Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies

被引:11
|
作者
Weichseldorfer, Matthew [1 ]
Tagaya, Yutaka [1 ,2 ]
Reitz, Marvin [1 ,2 ]
DeVico, Anthony L. [1 ,2 ]
Latinovic, Olga S. [1 ,3 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
HIV; AIDS pathogenesis; CCR5 coreceptor populations; Conformational changes; PRIMARY-CELLS IMPLICATIONS; CHEMOKINE RECEPTOR CCR5; PROTEIN FLSC IGG1; R5; HIV-1; SYNERGISTIC INHIBITION; MARAVIROC; INDIVIDUALS; MECHANISMS; RESISTANT; SURFACE;
D O I
10.1186/s12967-022-03243-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The chemokine receptor CCR5 is the major coreceptor for HIV-1 cell entry. We previously observed that not all CCR5 mAbs reduce HIV-1 infection, suggesting that only some CCR5 populations are permissive for HIV-1 entry. This study aims to better understand the relevant conformational states of the cellular coreceptor, CCR5, involved in HIV entry. We hypothesized that CCR5 assumes multiple configurations during normal cycling on the plasma membrane, but only particular forms facilitate HIV-1 infection. Methods To this end, we quantified different CCR5 populations using six CCR5 monoclonal antibodies (mAbs) with different epitope specificities and visualized them with super-resolution microscopy. We quantified each surface CCR5 population before and after HIV-1 infection. Results Based on CCR5 conformational changes, down-modulation, and trafficking rates (internalization and recycling kinetics), we were able to distinguish among heterogeneous CCR5 populations and thus which populations might best be targeted to inhibit HIV-1 entry. We assume that a decreased surface presence of a particular CCR5 subpopulation following infection means that it has been internalized due to HIV-1 entry, and that it therefore represents a highly relevant target for future antiviral therapy strategies. Strikingly, this was most true for antibody CTC8, which targets the N-terminal region of CCR5 and blocks viral entry more efficiently than it blocks chemokine binding. Conclusions Defining the virus-host interactions responsible for HIV-1 transmission, including specific coreceptor populations capable of establishing de novo infections, is essential for the development of an HIV-1 vaccine. This study hopefully will facilitate further development of inhibitors to block CCR5 usage by HIV-1, as well as inform future HIV-1 vaccine design.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Variation of CCR5AS lncRNA Enhances HIV-1 Infection Through Regulation of CCR5 Expression
    Zou, Sen
    VIRAL IMMUNOLOGY, 2020, 33 (08) : 536 - 538
  • [22] CCR5 as target for HIV-1 gene therapy
    Nazari, Reza
    Joshi, Sadhna
    CURRENT GENE THERAPY, 2008, 8 (04) : 264 - 272
  • [23] Evolution of Multiple Domains of the HIV-1 Envelope Glycoprotein during Coreceptor Switch with CCR5 Antagonist Therapy
    Du, Yueqi
    Wu, Ellen
    Gao, Xiang
    Zhang, Jie
    Martin, John C.
    Rosa, Bruce A.
    Mitreva, Makedonka
    Ratner, Lee
    MICROBIOLOGY SPECTRUM, 2022, 10 (04):
  • [24] Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors
    Chen, Wenwen
    Zhan, Peng
    De Clercq, Erik
    Liu, Xinyong
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (01) : 100 - 112
  • [25] Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor
    Gornalusse, German G.
    Mummidi, Srinivas
    Gaitan, Alvaro A.
    Jimenez, Fabio
    Ramsuran, Veron
    Picton, Anabela
    Rogers, Kristen
    Manoharan, Muthu Saravanan
    Avadhanam, Nymisha
    Murthy, Krishna K.
    Martinez, Hernan
    Murillo, Angela Molano
    Chykarenko, Zoya A.
    Hutt, Richard
    Daskalakis, Demetre
    Shostakovich-Koretskaya, Ludmila
    Karim, Salim Abdool
    Martin, Jeffrey N.
    Deeks, Steven G.
    Hecht, Frederick
    Sinclair, Elizabeth
    Clark, Robert A.
    Okulicz, Jason
    Valentine, Fred T.
    Martinson, Neil
    Tiemessen, Caroline Tanya
    Ndung'u, Thumbi
    Hunt, Peter W.
    He, Weijing
    Ahuja, Sunil K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (34) : E4762 - E4771
  • [26] Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach
    Gadhe, Changdev G.
    Kothandan, Gugan
    Cho, Seung Joo
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2013, 31 (11) : 1251 - 1276
  • [27] CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection
    Westrop, Samantha J.
    Moyle, Graeme
    Jackson, Akil
    Nelson, Mark
    Mandalia, Sundhiya
    Imami, Nesrina
    MOLECULAR MEDICINE, 2012, 18 (08) : 1240 - 1248
  • [28] HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro
    Moncunill, Gemma
    Armand-Ugon, Mercedes
    Pauls, Eduardo
    Clotet, Bonaventura
    Este, Jose A.
    AIDS, 2008, 22 (01) : 23 - 31
  • [29] Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES
    Nisius, Lydia
    Rogowski, Marco
    Vangelista, Luca
    Grzesiek, Stephan
    PROTEIN EXPRESSION AND PURIFICATION, 2008, 61 (02) : 155 - 162
  • [30] The promise of CCR5 antagonists as new therapies for HIV-1
    Repik, Alexander
    Richards, Kathryn H.
    Clapham, Paul R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 130 - 139